Equities analysts predict that Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will post $8.12 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Enanta Pharmaceuticals’ earnings. The lowest sales estimate is $7.53 million and the highest is $8.70 million. Enanta Pharmaceuticals reported sales of $13.98 million during the same quarter last year, which indicates a negative year-over-year growth rate of 41.9%. The business is scheduled to issue its next earnings results after the market closes on Monday, August 7th.

On average, analysts expect that Enanta Pharmaceuticals will report full year sales of $8.12 million for the current financial year, with estimates ranging from $75.36 million to $75.69 million. For the next fiscal year, analysts anticipate that the firm will report sales of $82.63 million per share, with estimates ranging from $80.78 million to $84.48 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, May 8th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.10. The firm had revenue of $9 million for the quarter, compared to analysts’ expectations of $9.19 million. Enanta Pharmaceuticals had a negative net margin of 28.68% and a negative return on equity of 4.94%. The business’s revenue was down 30.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.09) EPS.

ENTA has been the topic of several research analyst reports. Zacks Investment Research lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, May 12th. ValuEngine upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. JMP Securities upgraded shares of Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price on the stock in a research report on Tuesday, July 11th. Finally, BidaskClub lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Enanta Pharmaceuticals has a consensus rating of “Buy” and an average price target of $30.75.

COPYRIGHT VIOLATION WARNING: “$8.12 Million in Sales Expected for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) This Quarter” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/07/8-12-million-in-sales-expected-for-enanta-pharmaceuticals-inc-nasdaqenta-this-quarter.html.

Shares of Enanta Pharmaceuticals (ENTA) opened at 38.39 on Monday. The stock’s 50 day moving average is $36.29 and its 200 day moving average is $32.18. Enanta Pharmaceuticals has a 12 month low of $21.00 and a 12 month high of $39.05. The stock’s market capitalization is $732.60 million.

A number of institutional investors have recently bought and sold shares of ENTA. Mason Street Advisors LLC raised its position in Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock worth $100,000 after buying an additional 212 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in Enanta Pharmaceuticals by 3.5% in the second quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock worth $118,000 after buying an additional 110 shares during the last quarter. SG Americas Securities LLC raised its position in Enanta Pharmaceuticals by 5.8% in the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock worth $157,000 after buying an additional 237 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in Enanta Pharmaceuticals by 62.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock worth $159,000 after buying an additional 1,702 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth $204,000. Hedge funds and other institutional investors own 65.95% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.